Gynecologic Oncology Unit, Department of Gynaecology and Obstetrics, Hospital Universitario Donostia, San Sebastián, Spain (all authors)..
Gynecologic Oncology Unit, Department of Gynaecology and Obstetrics, Hospital Universitario Donostia, San Sebastián, Spain (all authors).
J Minim Invasive Gynecol. 2019 Jul-Aug;26(5):954-959. doi: 10.1016/j.jmig.2018.10.002. Epub 2018 Oct 5.
To assess the efficacy of Tissucol Duo (Baxter AG, Vienna, Austria) fibrin sealant in decreasing the incidence of lymphocele (LC) after pelvic laparoscopic lymph node dissection using harmonic shears.
Randomized controlled trial (Canadian Task Force classification level I).
Tertiary referral and educational center.
Seventy-four patients randomized to the use of sealant per hemipelvis.
Fibrin sealant.
After bilateral pelvic lymphadenectomy a fibrin sealant was used in 1 hemipelvis but not the other, applied in 41 patients (55.4%) to the left and 33 patients (44.6%) to the right hemipelvis. The primary outcome was the incidence of LC after surgery in symptomatic and asymptomatic patients. Imaging (ultrasound, computed tomography, and magnetic resonance) was performed to detect LC at 3, 6, and 12 months after surgery. Overall, 26 patients (35.1%) developed LC, and 4 were symptomatic (5.4%). Allowing patients to serve as their own treatment group and control, the hemipelvis treated with Tissucol Duo corresponding to the treatment group and that not treated to the control group, LCs were found in 17 (23%) and 14 (19%) cases, respectively, but the difference was not significant. The mean initial LC maximum diameter was 27.1 mm (standard deviaiotn, 35.2), and LCs tended to decrease in size during the first year to a mean of 8.7 mm.
Application of Tissucol Duo fibrin sealant after laparoscopic pelvic lymphadenectomy using ultrasonic shears does not decrease the occurrence of symptomatic or asymptomatic LC.
评估泰丝可双(Baxter AG,维也纳,奥地利)纤维蛋白胶在使用超声刀进行盆腔腹腔镜淋巴结清扫术后减少淋巴囊肿(LC)发生率的效果。
随机对照试验(加拿大任务组分类水平 I)。
三级转诊和教育中心。
74 名患者随机分为每半骨盆使用密封剂。
纤维蛋白胶。
在双侧盆腔淋巴结清扫术后,在 41 名患者(55.4%)左侧和 33 名患者(44.6%)右侧半骨盆中使用纤维蛋白胶。主要结果是手术后有症状和无症状患者的 LC 发生率。手术后 3、6 和 12 个月进行影像学(超声、计算机断层扫描和磁共振成像)以检测 LC。总体而言,26 名患者(35.1%)发生 LC,4 名患者有症状(5.4%)。允许患者作为自己的治疗组和对照组,用泰丝可双治疗的半骨盆为治疗组,未治疗的为对照组,LC 在 17 例(23%)和 14 例(19%)中发现,但差异无统计学意义。初始 LC 最大直径的平均值为 27.1 毫米(标准偏差,35.2),LC 在第一年趋于减小,平均直径为 8.7 毫米。
在使用超声刀进行腹腔镜盆腔淋巴结清扫术后应用泰丝可双纤维蛋白胶不能降低有症状或无症状 LC 的发生。